Articles from Valo Health, Inc.

Valo Health, Inc. (“Valo”) and Montai Therapeutics today announced a merger to form a leading drug discovery platform powered by human evidence. By uniting Valo’s AI-enabled human causal biology and predictive chemistry capabilities with Montai’s proven chemistry platform and clinical-stage immunology and inflammation (I&I) pipeline, the combined company will have expanded discovery capabilities, data, and models to develop new medicines for novel and hard-to-drug biology. Brian Alexander, MD, MPH, CEO of Valo and CEO-Partner at Flagship Pioneering, will lead the combined company, which will retain the Valo Health name.

Valo Health, Inc. (“Valo”), a pioneer in the use of human data and AI to accelerate drug discovery and development, today announced the appointment of Chris Anagnostopoulos, PhD, C.Stat, to the newly created position of Chief Causal AI Officer. In this role, Dr. Anagnostopoulos will lead the advancement of Valo’s human causal biology platform, translating large-scale, real‑world human data into causal insights that inform drug discovery.

Valo Health, Inc. (“Valo”), a company pioneering the use of human data and AI to accelerate drug discovery and development, today announced the appointment of Karin Conde-Knape, Ph.D., as Chief Scientific Officer (CSO). Dr. Conde-Knape brings more than two decades of expertise in drug development and translational science and a passion for patient-centric innovation.

Valo Health, Inc. (“Valo”), a company pioneering the use of human data and AI to accelerate drug discovery and development, today announced the appointment of Rita Kale as Chief Financial Officer (CFO). Rita brings more than two decades of global finance leadership in biopharma, diagnostics, and technology-enabled healthcare.

Valo Health, Inc. (“Valo”), a company pioneering the use of human data and AI to accelerate drug discovery and development, today announced a strategic collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to advance therapeutic discovery in Parkinson’s disease and related disorders. The partnership will leverage Valo’s AI-enabled human causal biology platform to identify and validate novel disease targets and its closed loop discovery platform to rapidly generate preclinical compounds. The partnership includes upfront and potential milestone payments totaling up to over 3 billion dollars, as well as royalties and R&D funding.

Valo Health, Inc. (“Valo”), a company using human data and AI to rapidly discover and develop new medicines, today announced that it has been awarded a research grant from The Michael J. Fox Foundation (MJFF) as part of its Targets to Therapies Initiative, which aims to expand the number of promising druggable biological targets in Parkinson’s disease (PD). Valo was selected for its expertise in leveraging robust human data sets and advanced AI-enabled analytical tools to understand the underlying causes of disease and prioritize targets for new medicines.

Valo Health, Inc. (“Valo”), a biotechnology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence (AI), today announced the appointment of Peggy Dalicandro as Vice President, Head of Human Resources. In this newly created role, Dalicandro will shape Valo’s human capital strategy, lead talent acquisition, and support the scaling of the company.

Valo Health, Inc. (“Valo”), a biotechnology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence (AI), today announced a multi-year collaboration with nference, a company dedicated to transforming healthcare by making biomedical knowledge computable. The research collaboration will leverage decades of comprehensive, HIPAA-compliant, fully de-identified patient-level data from the nference federated AI network to enhance the capabilities of Valo’s Opal Computational Platform™, enabling advances in the discovery and development of drug targets and precision medicines.